A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Clinical trial NCT06969612 · RECRUITING

Trial details

NCT number: NCT06969612
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)

Start date: 2025-05-15
Primary completion: 2027-05-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.